missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ PD-L1/CD47 Biosimilar Recombinant Human Monoclonal Antibody

PD-L1/CD47 Biosimilar Recombinant Monoclonal Antibody

£483.00 - £2005.00

Specifications

Antigen PD-L1/CD47 Biosimilar
Concentration 1 mg/mL
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Applications ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
Classification Recombinant Monoclonal
View More Specs

Products 2
Product Code Brand Quantity Price Quantity & Availability  
Product Code Brand Quantity Price Quantity & Availability  
30282840
View Documents
Invitrogen™
MA560155
100 μg
£483.00
100µg
View alternative products
Save Up to 
»
Please to purchase this item. Need a web account? Register with us today!
30284147
View Documents
Invitrogen™
MA560156
1 mg
£2005.00
1mg
View alternative products
Save Up to 
»
Please to purchase this item. Need a web account? Register with us today!
Description

Description

PD-L1/CD47 Biosimilar Recombinant Monoclonal Antibody for SPR, Flow, ELISA, Functional

Programmed Cell Death Ligand 1 (PD-L1) and Cluster of Differentiation 47 (CD47) are two significant molecules involved in the immune evasion mechanisms of cancer cells. PD-L1, encoded by the CD274 gene, is a transmembrane protein that interacts with the PD-1 receptor on T-cells, leading to the inhibition of T-cell activation and proliferation, thus allowing cancer cells to evade immune detection. This pathway is targeted by several immunotherapeutic drugs, including pembrolizumab and nivolumab, which have shown effectiveness in treating various cancers. On the other hand, CD47, a transmembrane protein encoded by the CD47 gene, sends a don't eat me signal by binding to the Signal-Regulatory Protein Alpha (SIRP alpha) on myeloid cells, thereby inhibiting phagocytosis of cancer cells by macrophages. Overexpression of CD47 is observed in many tumors and is associated with poor prognosis. Therapeutic strategies targeting the CD47-SIRP alpha axis are being developed to enhance the phagocytosis of cancer cells and improve anti-tumor immunity. Both PD-L1 and CD47 play crucial roles in the tumor microenvironment by helping cancer cells evade immune destruction, and targeting these pathways has become a promising approach in cancer immunotherapy.
Specifications

Specifications

PD-L1/CD47 Biosimilar
-20°C, Avoid Freeze/Thaw Cycles
Recombinant Monoclonal
Lyophilized
IgG1
Human
Primary
Protein A
1 mg/mL
ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
Unconjugated
Human
RUO
25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2
Antibody
Videos
SDS
Documents

Documents

Product Certifications
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.